Abstracts tagged "Connective tissue diseases"

Abstract Number: 2413 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Mixed Connective Tissue Disease: Results from a Multicentre Cohort Study
Massimo Radin¹, Karen Schreiber², Maria Jose Cuadrado³, Irene Cecchi⁴, Laura Andreoli⁵, Franco Franceschini⁶, Maria Teresa Caleiro⁷, Danieli Andrade⁸, Elena Gibbone⁹, Munther A Khamashta¹⁰, Jill P. Buyon¹¹, Peter M. Izmirly¹², Maria Aguirre¹³, Chiara Benedetto⁹, Dario Roccatello¹⁴, Luca Marozio¹⁵ and Savino Sciascia¹⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Clinica Universidad de Navarra, Madrid, Spain, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ⁷Rheumatology, University of São Paulo, Tucson, AZ, ⁸Rheumatology, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁹University of Turin, Turin, Italy, ¹⁰Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ¹¹Medicine, New York University School of Medicine, New York, NY, ¹²NYU Langone Health, New York, NY, ¹³IMIBIC, Cordoba, Cordoba, Spain, ¹⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ¹⁵University of Turin, Torino, Italy, ¹⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Mixed connective tissue disease (MCTD) is characterized by signs and symptoms of a combination of disorders, primarily systemic lupus erythematosus (SLE), scleroderma and polymyositis…
Abstract Number: 2433 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Undifferentiated Connective Tissue Disease- a Single Academic Center’s Experience
Katherine Kaufman¹, Amanda M. Eudy¹, Nathaniel J. Harris², Laura Neil³ and Megan E. B. Clowse¹, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ²Department of Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC
Background/Purpose: SLE patients have poorer pregnancy outcomes than healthy patients, including a lower rate of live birth and higher rates of small for gestational age…
Abstract Number: 1687 • 2017 ACR/ARHP Annual Meeting
Efficacy of Rituximab for Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Study of 28 Patients
Sunny Patel¹, Samina Hayat², Gloria Caldito³ and Kristen Erickstad¹, ¹Rheumatology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, ²Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, ³Neurology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA
Background/Purpose: Interstitial lung disease (ILD) is a severe pulmonary complication associated with connective tissue diseases (CTDs), resulting in substantial morbidity and mortality. Despite advances in…
Abstract Number: 2035 • 2017 ACR/ARHP Annual Meeting
Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
Sahil Koppikar¹ and Henry Averns², ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Private Practice, Kingston, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is used widely for the treatment of inflammatory arthritides and systemic lupus erythematosus. Recent publications have shown that HCQ toxicity is not…
Abstract Number: 2105 • 2017 ACR/ARHP Annual Meeting
Epidemiology of Interstitial Pneumonia with Autoimmune Features
Robert Mango¹, Ashima Makol², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) with clinical features suggestive of, but not sufficient for, a…
Abstract Number: 2114 • 2017 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?
Sepehr Mesdaghinia¹, Julio Arturo Huapaya², Brainerd Ewarien² and Virginia D. Steen¹, ¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²Medicine, MedStar Georgetown University Hospital, Washington, DC
- Background/Purpose: Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD). It is important to separate these patients…
Abstract Number: 2169 • 2017 ACR/ARHP Annual Meeting
A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Kimberly A. Rehberg¹, Morgan M. Brown², Anna K. Shmagel¹, Elie Gertner³ and Jerry A. Molitor¹, ¹Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²HealthPartners Institute, St. Paul, MN, ³Section of Rheumatology, Regions Hospital, St. Paul, MN
Background/Purpose: Recent studies have suggested the possible benefit of the anti-CD20 agent Rituximab (RTX) in autoimmune myositis (AIM). As AIM is a rare and heterogeneous…
Abstract Number: 2677 • 2017 ACR/ARHP Annual Meeting
Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience
Lindsey A. MacFarlane¹ and Paul F. Dellaripa², ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women’s Hospital, Boston, MD
Background/Purpose: The evaluation of patients who develop interstitial lung disease (ILD) includes an assessment for underlying rheumatic disease or connective tissue disease (CTD). Delineating a…
Abstract Number: 258 • 2017 ACR/ARHP Annual Meeting
Prevalence of Echocardiographic Findings in Connective Tissue Diseases – a Retrospective Cohort Study
Valentin S. Schäfer¹, Katharina Weiss², Andreas Krause² and Wolfgang A. Schmidt³, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Echocardiography is frequently performed in patients with connective tissue diseases (CTD), mostly to evaluate cardiac involvement or development of pulmonary arterial hypertension (paH). Despite…
Abstract Number: 275 • 2017 ACR/ARHP Annual Meeting
Predictive Factors of Cytomegalovirus Infection in Patients with Connective Tissue Diseases Treated with Immunosuppressive Drugs
Yusuke Yoshida¹, Hiroki Kohno², Katsuhiro Oi³, Tadahiro Tokunaga³, Tatsuomi Kuranobu³, Takaki Nojima⁴, Shintaro Hirata³ and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Prefectural Hospital, Hiroshima, Japan, ³Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁴Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Cytomegalovirus (CMV) infections occur frequently in immunocompromised patients. This disease will be fatal if proper treatment is not done. Therefore, in the treatment of…
Abstract Number: 1292 • 2017 ACR/ARHP Annual Meeting
Long-Term Follow-up of 320 Chilren Born to Mothers with Systemic Autoimmune Diseases: A Multicentre Survey from 24 Rheumatology Centers in Italy
Maria Grazia Lazzaroni¹, Cecilia Nalli¹, Laura Andreoli¹, Chiara Carini¹, Marilia Rodrigues², Francesca Dall'Ara¹, Elena Bartoloni-Bocci³, Roberto Gerli³, Maria Gerosa⁴, Cecilia B. Chighizola⁵, Pier Luigi Meroni⁴, Luigi Sinigaglia⁶, Paola Conigliaro⁷, Roberto Perricone⁷, Ada Corrado⁸, Francesco Paolo Cantatore⁸, Salvatore D'Angelo⁹, Ignazio Olivieri⁹, Maria Favaro¹⁰, Maddalena Larosa¹⁰, Andrea Doria¹⁰, Amelia Ruffatti¹¹, Elena Generali¹², Carlo Selmi¹³, Marianna Meroni¹⁴, Maurizio Cutolo¹⁵, Melissa Padovan¹⁶, Marcello Govoni¹⁶, Giulia Pazzola¹⁷, Carlo Salvarani¹⁸, Susanna Peccatori¹⁹, Giuseppe Paolazzi¹⁹, Imma Prevete²⁰, Giovanni Minisola²⁰, Gian Domenico Sebastiani²¹, Antonio Brucato²², Véronique Ramoni²³, Roberto Caporali²⁴, Carlomaurizio Montecucco²⁴, Viola Signorini²⁵, Chiara Tani²⁶, Marta Mosca²⁵, Marica Trevisani²⁷, Nazzarena Malavolta²⁷, Marta Vadacca²⁸, Antonella Afeltra²⁹, Ester Vivaldelli³⁰, Armin Maier³⁰, Elisa Visalli³¹, Rosario Foti³¹, Carolina Benigno³², Lucia Zuliani³³, Armando Gabrielli³³, Corrado Campochiaro³⁴, Elena Baldissera³⁵, Maria Grazia Sabbadini³⁶, Nicoletta Romeo³⁷ and Angela Tincani¹, ¹University and Spedali Civili of Brescia, Brescia, Italy, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³University and Azienda Ospedaliera of Perugia, Perugia, Italy, ⁴Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁵Rheumatology, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, ⁶Istituto Ortopedico Gaetano Pini, University of Milan, Italy, Milan, Italy, ⁷Policlinico Tor Vergata of Rome, Rome, Italy, ⁸Ospedali Riuniti of Foggia, Foggia, Italy, ⁹San Carlo Hospital of Potenza, Potenza, Italy, ¹⁰University and Azienda Ospedaliera of Padova, Padova, Italy, ¹¹Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, ¹²Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ¹³Humanitas Research Hospital of Milan, Rozzano, Italy, ¹⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ¹⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ¹⁶UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ¹⁷Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico of Reggio-Emilia, Reggio-Emilia, Italy, ¹⁸Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy, ¹⁹Azienda Provinciale Servizi Sanitari of Trento, Trento, Italy, ²⁰Azienda Ospedaliera San Camillo of Rome, Roma, Italy, ²¹Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ²²Struttura Complessa Medicina Interna, ASST Papa Giovanni XXIII, Bergamo, Italy, ²³Ospedale Papa Giovanni XXIII of Bergamo, Policlinico San Matteo of Pavia, Bergamo, Pavia, Italy, ²⁴University and Policlinico San Matteo of Pavia, Pavia, Italy, ²⁵University of Pisa, Pisa, Italy, ²⁶Rheumatology Unit, University of Pisa, Pisa, Italy, ²⁷Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy, ²⁸University Campus Biomedico of Rome, Roma, Italy, ²⁹University Campus Biomedico of Rome, roma, Italy, ³⁰Ospedale of Bolzano, Bolzano, Italy, ³¹Policlinico Vittorio Emanuele-Ferrarotto-Bambin Gesù of Catania, Catania, Italy, ³²University Federico II of Napoli, Napoli, Italy, ³³Ospedali Riuniti of Ancona, Ancona, Italy, ³⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ³⁵Ospedale San Raffaele of Milan, Milan, Italy, ³⁶Unit of Medicine and Clinical Immunology, Ospedale San Raffaele of Milano, Milan, Italy, ³⁷Ospedale S.Croce e Carle of Cuneo, Cuneo, Italy
Background/Purpose: Rheumatic Diseases (RD) frequently affect women during reproductive age, therefore counseling on family planning is crucial for their quality of life. Children's outcome is…
Abstract Number: 1001 • 2016 ACR/ARHP Annual Meeting
Cytomegalovirus Reactivation in Connective Tissue Disease By Immunosuppressive Therapy Predicts Severe Infection and High Mortality
Yuichiro Ota¹, Yuko Kaneko² and Tsutomu Takeuchi³, ¹Division of Rheumatology, Department of Internal Medicine., Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Intensive immunosuppressive treatment for remission induction in connective tissue diseases (CTDs) sometimes causes serious infection. Cytomegalovirus (CMV) is a herpesvirus remaining latent after primary…
Abstract Number: 1344 • 2016 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Severe Pulmonary Hemorrhage Related to Systemic Disease: French Multicentric Study
Adrien Mirouse¹, Antoine Parrot², Jacques Cadranel³, Eric Mariotte⁴, Julien Mayaux⁵, Nicolas Bréchot⁶, Mathieu Vautier⁷, Etienne de Montmollin⁸, Nicolas de Prost⁹, Patrice Cacoub¹⁰ and David Saadooun¹⁰, ¹Service de médecine interne, Hôpital Saint-Antoine, Paris, France, ²Service de pneumologie, Hôpital Tenon, 75020, France, ³Service de pneumologie, Hôpital Tenon, Paris, France, ⁴Service de réanimation médicale, Hôpital Saint-Louis, Paris, France, ⁵Service de pneumologie et réanimation médicale, Hôpital Pitié-Salpêtrière, Paris, France, ⁶Service de réanimation médicale, Hôpital Pitié-Salpêtrière, Paris, France, ⁷Service de médecine interne, CHU de Caen, Caen, France, ⁸Service de réanimation médicale, Hôpital Delafontaine, Saint-Denis, France, ⁹Service de réanimation médicale, Hôpital Henri Mondor, Créteil, France, ¹⁰Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France
Background/Purpose: pulmonary hemorrhage (PH) may complicate systemic disease. The main objective of this study was to describe characteristics, treatment and outcome of patients presenting severe…
Abstract Number: 1345 • 2016 ACR/ARHP Annual Meeting
Undifferentiated Connective Tissue Disease: A 121 Patients Audit Focusing on Initial Diagnosis and Changes over Time
Maria Leandro^1,2 and Raluca Ionescu^3,4, ¹Rheumatology, University College London Hospitals, London, United Kingdom, ²University College London, London, Uruguay, ³University College London Hospitals, London, United Kingdom, ⁴Sfanta Maria Hospital, Bucharest, Romania
Background/Purpose: The diagnosis of Undifferentiated Connective Tissue Disease (UCTD) has raised controversy over the years regarding making the diagnosis, evolution and prognosis. Le Roy et…
Abstract Number: 1351 • 2016 ACR/ARHP Annual Meeting
Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Mitsuhiro Akiyama¹, Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].